Causes of immune dysfunction in hyperbilirubinemia model rats

Area of Science:

• Immunology
• Neonatology
• Toxicology

Background:

• Neonatal hyperbilirubinemia is a common condition that can lead to immune dysfunction.
• The mechanisms underlying bilirubin-induced immune suppression are not fully understood.
• Lipopolysaccharide (LPS) is a potent immune stimulant used to model inflammatory responses.

Purpose of the Study:

• To investigate the impact of hyperbilirubinemia on immune function in neonatal rats.
• To explore the role of bilirubin concentration in modulating immune responses.
• To elucidate the molecular mechanisms of immune dysfunction induced by hyperbilirubinemia.

Main Methods:

• Neonatal Sprague-Dawley rats were divided into control and bilirubin-treated groups (low and high dose).
• Lipopolysaccharide (LPS) was administered to induce an inflammatory response.
• Spleen tissues were analyzed for apoptosis, MyD88, and p-TAK1 expression. Serum cytokines and T cell subsets were quantified.

Main Results:

• High-dose bilirubin, in conjunction with LPS, significantly increased spleen cell apoptosis compared to low-dose bilirubin.
• High bilirubin levels reduced p-TAK1 expression and inhibited the NF-κB pathway.
• Elevated inflammatory factors and altered T cell distribution (increased CD8+, decreased CD4+) were observed in the high-dose group.

Conclusions:

• High-concentration bilirubin exacerbates LPS-induced inflammation and immune suppression in neonatal rats.
• Inhibition of the NF-κB signaling pathway is a key mechanism underlying bilirubin-induced immune dysfunction.
• Hyperbilirubinemia contributes to an inflammatory cascade, resulting in compromised immune function.